​

Reviva Pharmaceuticals (RVPH) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RVPH Stock Rating

Reviva Pharmaceuticals stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

RVPH Price Target Upside V Benchmarks

TypeNameUpside
StockReviva Pharmaceuticals-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.78$0.78$0.78
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2533---6
May, 2533---6
Apr, 2533---6
Mar, 2533---6
Feb, 2533---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 23, 2024EF HuttonBuyinitialise
Jun 11, 2024H.C. WainwrightBuyBuyhold
Jan 24, 2022H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.25$-1.65-----
Avg Forecast$-1.09$-1.60$-0.98$-0.84$-0.83$0.78$2.08
High Forecast$-1.09$-1.48$-0.96$-0.76$-0.48$0.98$2.08
Low Forecast$-1.09$-1.71$-1.01$-0.91$-1.30$0.58$2.08
Surprise %14.68%3.13%-----

Revenue Forecast

$135M $153M $171M $189M $207M $225M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast----$220.44M$137.30M$137.99M
High Forecast----$220.44M$137.30M$137.99M
Low Forecast----$220.44M$137.30M$137.99M
Surprise %-------

Net Income Forecast

$-40T $-31T $-22T $-13T $-4T $5T Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-24.34M$-39.26T-----
Avg Forecast$-21.27M$-39.26M$-23.52M$-19.82M$-21.23M$18.56M$49.50M
High Forecast$-21.27M$-35.13M$-22.92M$-18.04M$-11.50M$23.33M$49.50M
Low Forecast$-21.27M$-40.78M$-24.13M$-21.59M$-30.96M$13.80M$49.50M
Surprise %14.41%99999900.00%-----

RVPH Forecast FAQ

Is Reviva Pharmaceuticals stock a buy?

Reviva Pharmaceuticals stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Reviva Pharmaceuticals is a favorable investment for most analysts.

What is Reviva Pharmaceuticals's price target?

Reviva Pharmaceuticals's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.78.

How does Reviva Pharmaceuticals stock forecast compare to its benchmarks?

Reviva Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Reviva Pharmaceuticals over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Reviva Pharmaceuticals’s EPS forecast?

Reviva Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.98, marking a -40.61% decrease from the reported $-1.65 in 2023. Estimates for the following years are $-0.84 in 2025, $-0.83 in 2026, $0.78 in 2027, and $2.08 in 2028.

What is Reviva Pharmaceuticals’s revenue forecast?

Reviva Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $220.44M for 2026, $137.3M for 2027, and $137.99M for 2028.

What is Reviva Pharmaceuticals’s net income forecast?

Reviva Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $-23.522M, representing a -100.00% decrease from the reported $-39.261T in 2023. Projections indicate $-19.816M in 2025, $-21.226M in 2026, $18.56M in 2027, and $49.5M in 2028.